HER2 (ERBB2) overexpression varied according to gastric cancer subtypes and targeting HER2 through the use of a humanized monoclonal antibody Trastuzumab (Herceptin) has been very successful in the treatment of HER2-overexpressed gastric cancers [31]. The gene discussed is ERBB2; the disease is gastric cancer.